Maxim Group analyst Jason McCarthy maintained a Buy rating on VolitionRX (VNRX – Research Report) yesterday. The company’s shares opened today at $1.24.
McCarthy covers the Healthcare sector, focusing on stocks such as Oncolytics Biotech, Daré Bioscience, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -31.0% and a 19.03% success rate on recommended stocks.
VolitionRX has an analyst consensus of Strong Buy, with a price target consensus of $4.67, implying a 276.61% upside from current levels. In a report released on August 16, Cantor Fitzgerald also maintained a Buy rating on the stock with a $2.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on VolitionRX’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $216.31 thousand and a GAAP net loss of $9.55 million. In comparison, last year the company earned a revenue of $39.75 thousand and had a GAAP net loss of $7.73 million
Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VNRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Austin, TX.
Read More on VNRX:
